Arctoris and SpiroChem enter into strategic partnership to accelerate drug discovery

Arctoris, a leading contract research organisation (CRO) advancing drug discovery experimentation through its automated laboratory and data science platform, Ulysses^®, has entered into a joint partnership with SpiroChem AG.

The partnership combines Arctoris' automated biology capabilities with SpiroChem's medicinal and synthetic chemistry platforms including photochemistry, electrochemistry, flow chemistry, and parallel solid-phase synthesis.

This unique combination of biological and chemistry expertise provides a novel end-to-end drug discovery solution that:

• Accelerates timelines from hit identification to candidate selection
• Enhances data quality and reproducibility through automation
• Provides access to diverse chemical space and novel scaffolds
• Offers complete project support, scientific consulting, and logistics management
• Comprises flexible engagement models tailored to specific project needs

Tom Fleming, CEO of Arctoris, said, "By joining forces with SpiroChem, we're creating a powerhouse in drug discovery with the potential to significantly accelerate their drug discovery timelines. The partnership combines our automated biology platform with SpiroChem's innovative chemistry platforms to offer biotech and pharma organisations a highly differentiated integrated cutting-edge solution."

Want the latest science news straight to your inbox? Become a SelectScience member for free today>>